Meningococcal Disease (DBCOND0033309)

Identifiers

Synonyms

Meningococcal disease / Meningococcal infection, unspecified / Meningococcal infectious disease (disorder) / Meningococcal infection / Unspecified meningococcal infection / Meningococcal Infections / Neisseria meningitidis infection NOS

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen	This antigen is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. It is approved for use in individuals 10...	No drug targets
Neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen	Neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen is a vaccine.	No drug targets

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01452464	Safety of MenACWY-CRM Vaccination in Adolescents	No drug interventions	Not Available	Not Available	completed
NCT01139021	One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age	No drug interventions	prevention	3	completed
NCT01423084	Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years	No drug interventions	prevention	3	completed
NCT01705379	Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older	No drug interventions	Not Available	Not Available	withdrawn
NCT01466387	A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) Rabies virus inactivated antigen, A Typhoid Vi polysaccharide vaccine Yellow fever vaccine	prevention	3	completed
NCT01000311	A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months	Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Bordetella pertussis fimbriae 2/3 antigen Bordetella pertussis pertactin antigen Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Hepatitis B Vaccine (Recombinant) Measles virus vaccine live attenuated Mumps virus strain B level jeryl lynn live antigen Poliovirus type 1 antigen (formaldehyde inactivated) Poliovirus type 2 antigen (formaldehyde inactivated) Poliovirus type 3 antigen (formaldehyde inactivated) Rubella virus vaccine Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 14 capsular polysaccharide antigen Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 18C capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 18c capsular polysaccharide antigen Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 19a capsular polysaccharide antigen Streptococcus pneumoniae type 19f capsular polysaccharide antigen Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 23f capsular polysaccharide antigen Streptococcus pneumoniae type 3 capsular polysaccharide antigen Streptococcus pneumoniae type 4 capsular polysaccharide antigen Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 5 capsular polysaccharide antigen Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 6b capsular polysaccharide antigen Streptococcus pneumoniae type 7f capsular polysaccharide antigen Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 9v capsular polysaccharide antigen	prevention	3	completed
NCT01430611	Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children	No drug interventions	prevention	4	completed
NCT02287688	Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study	Corynebacterium diphtheriae CRM197 protein	Not Available	Not Available	completed
NCT01210885	Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents	No drug interventions	prevention	2	completed
NCT01766206	Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea	Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal polysaccharide vaccine group A Meningococcal polysaccharide vaccine group C Meningococcal polysaccharide vaccine group W-135 Meningococcal polysaccharide vaccine group Y	prevention	4	completed
NCT00329849	Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age	No drug interventions	prevention	3	completed
NCT01992536	Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)	No drug interventions	prevention	2	completed
NCT00661713	Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules	No drug interventions	prevention	2 / 3	completed
NCT00560313	Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults	No drug interventions	prevention	2	completed
NCT01973218	Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.	Corynebacterium diphtheriae CRM197 protein	prevention	3	completed
NCT00944034	Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12	No drug interventions	prevention	2 / 3	completed
NCT01896596	Hepatitis B Vaccination in Infants	Clostridium tetani toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae Meningococcal polysaccharide vaccine group C	prevention	4	completed
NCT01367158	Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines	Corynebacterium diphtheriae CRM197 protein	prevention	2	completed
NCT03089086	South Australian Meningococcal B Vaccine Herd Immunity Study	Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup b fhbp fusion protein antigen Neisseria meningitidis serogroup b nada protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen	prevention	4	completed
NCT04239430	Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study	No drug interventions	Not Available	Not Available	unknown_status
NCT01453348	Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine	Hepatitis A Vaccine Hepatitis B Vaccine (Recombinant)	prevention	3	completed
NCT01026974	Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine	No drug interventions	prevention	2	completed
NCT02811120	PRIME Follow up - Quadri Meningo Vacinees	No drug interventions	Not Available	Not Available	completed
NCT00728260	36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds	Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen	Not Available	Not Available	completed
NCT02140762	Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents	Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal polysaccharide vaccine group A Meningococcal polysaccharide vaccine group C Meningococcal polysaccharide vaccine group W-135 Meningococcal polysaccharide vaccine group Y	prevention	2	completed
NCT01434680	Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers	Salicylic acid	prevention	2	completed
NCT00254995	Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine	No drug interventions	Not Available	Not Available	completed
NCT01339923	A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years	No drug interventions	prevention	3	completed
NCT01452438	Safety Surveillance of MenACWY-CRM Vaccine in Children	No drug interventions	Not Available	Not Available	completed
NCT01717638	Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1	No drug interventions	prevention	3	completed
NCT01270503	Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines	Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Meningococcal polysaccharide vaccine group C Meningococcal polysaccharide vaccine group W-135 Meningococcal polysaccharide vaccine group Y	prevention	4	completed
NCT01345721	Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine	No drug interventions	prevention	3	completed
NCT01027351	Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine	No drug interventions	prevention	2	completed
NCT02285777	Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents	No drug interventions	prevention	2	completed
NCT01478347	A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults	No drug interventions	prevention	3	completed
NCT00847145	Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers	No drug interventions	prevention	3	completed
NCT01274897	A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea	No drug interventions	prevention	3	completed
NCT00488683	B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants	Aluminium phosphate Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Bordetella pertussis fimbriae 2/3 antigen Bordetella pertussis pertactin antigen Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Measles virus vaccine live attenuated Mumps virus strain B level jeryl lynn live antigen Poliovirus type 1 antigen (formaldehyde inactivated) Poliovirus type 2 antigen (formaldehyde inactivated) Poliovirus type 3 antigen (formaldehyde inactivated) Rubella virus vaccine Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 18C capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen	prevention	2	completed
NCT01303211	A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger	No drug interventions	Not Available	Not Available	withdrawn
NCT01214837	Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life	No drug interventions	prevention	3	completed
NCT02223637	Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry	Corynebacterium diphtheriae CRM197 protein	Not Available	Not Available	completed
NCT01018732	A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY	No drug interventions	prevention	2	completed
NCT04398849	Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)	No drug interventions	Not Available	Not Available	recruiting
NCT01823536	Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose	Corynebacterium diphtheriae CRM197 protein	prevention	4	completed
NCT01725217	Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia	No drug interventions	prevention	3	completed
NCT00297817	Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents	No drug interventions	prevention	2	completed
NCT01148524	Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10	No drug interventions	prevention	2 / 3	completed
NCT03125616	Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B	Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup b fhbp fusion protein antigen Neisseria meningitidis serogroup b nada protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen	prevention	4	completed
NCT02141516	Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.	No drug interventions	prevention	3	completed
NCT03378258	Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.	No drug interventions	Not Available	Not Available	completed
NCT01984125	Testing the Use of Prompts to Increase Adolescent Immunization Rates	No drug interventions	health_services_research	Not Available	completed
NCT01782066	Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines	Clostridium tetani toxoid antigen (formaldehyde inactivated) Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal polysaccharide vaccine group A Meningococcal polysaccharide vaccine group C Meningococcal polysaccharide vaccine group W-135 Meningococcal polysaccharide vaccine group Y	prevention	1 / 2	completed
NCT00601731	Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months	Corynebacterium diphtheriae CRM197 protein	prevention	2	completed
NCT01682876	Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.	No drug interventions	prevention	3	completed
NCT01994629	Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers	No drug interventions	prevention	2	completed
NCT04023929	Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays	No drug interventions	Not Available	Not Available	unknown_status
NCT01642589	Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea	Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Bordetella pertussis fimbriae 2/3 antigen Bordetella pertussis pertactin antigen Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Meningococcal polysaccharide vaccine group C Meningococcal polysaccharide vaccine group W-135 Meningococcal polysaccharide vaccine group Y Pertussis vaccine	prevention	3	completed
NCT00329901	Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years	Pertussis vaccine	prevention	3	completed
NCT02173704	Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.	Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup b fhbp fusion protein antigen Neisseria meningitidis serogroup b nada protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen	prevention	3	completed
NCT00433914	Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants	No drug interventions	prevention	2	completed
NCT02451514	A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)	No drug interventions	prevention	2	completed
NCT01593514	Understanding the Immune Response to Two Different Meningitis Vaccines	Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal polysaccharide vaccine group A Meningococcal polysaccharide vaccine group C Meningococcal polysaccharide vaccine group W-135 Meningococcal polysaccharide vaccine group Y	basic_science	4	completed